ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Lanxess plans to increase its annual capacity for ethylene propylene-diene rubber to more than 140,000 metric tons through process improvements at its sites in Marl, Germany, and Orange, Texas, by 2008.
Solutia and FMC have settled a lawsuit in which Solutia alleged that FMC did not disclose the failure of purified phosphoric acid technology provided by FMC to the firms' Astaris joint venture. FMC will pay Solutia $22.5 million in cash.
Digital Specialty Chemicals, a Canadian maker of organophosphorus and organometallic chemicals, has completed an expansion of its Toronto facility. The firm says it has achieved a 50% rise in reactor capacity and a 10-fold increase in distillation throughput.
Solvay has started up a 10,000-metric-ton-per-year epichlorohydrin plant in Tavaux, France, based on glycerin obtained as a by-product from biodiesel production. The firm plans to start up a similar 100,000-metric-ton-per year unit in Thailand in 2009.
Broin, the ethanol producer, has changed its name to Poet. To move ahead, CEO Jeff Broin says, the company needed a name to better reflect what it does. Using a bit of poetic license, Broin explains, the firm harnesses creativity as poets do, by "leaving things better than we found them."
Dalton Pharma Services has signed a medicinal chemistry pact with Boehringer Ingelheim's Canadian arm. Toronto-based Dalton will design and synthesize novel compounds against a number of antiviral targets selected by Boehringer.
Regeneron Pharmaceuticals has licensed to Astellas Pharma its VelocImmune technology for human monoclonal antibody drug discovery. AstraZeneca will pay $20 million up front and make up to five additional annual payments of $20 million.
Codexis has signed up Merck & Co. as the first subscriber to its Codex biocatalyst panels product. Under a three-year deal, Merck will get access to Codexis biocatalysts for in-house application to its new-drug pipeline.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter